Factors affecting prognosis in canine subcutaneous mast cell tumors: 45 cases

Author:

Cherzan Nathan L.1,Fryer Katy1,Burke Blaise1,Farrelly John2

Affiliation:

1. Veterinary Specialty Hospital Sorrento Valley San Diego California USA

2. Blue Pearl Veterinary Partners New York New York USA

Abstract

AbstractObjectiveTo evaluate the clinical outcome of subcutaneous mast cell tumors (SQMCT) and to identify clinical and histological characteristics of more aggressive disease.Study designRetrospective study.AnimalsForty‐five dogs with 48 SQMCTs.MethodsMedical records were reviewed (2011–2021) for patient information, clinical, and histopathological data including multinucleation, necrosis, invasion into local muscle, an infiltrative growth pattern, tumor grade (if listed), mitotic index, and surgical margins. The presence of local recurrence, lymph node metastasis, survival time, and other parameters evaluating patient outcome were also recorded.ResultsLocal recurrence occurred in 17.8% (8/45) of dogs, 11.1% (5/45) developed metastatic recurrence, and 26.7% (12/45) developed lymph node metastasis. Dogs with lymph node metastases had a median disease‐free interval (DFI) of 194 days (18–1864), while median DFI was not reached for dogs without lymph node metastasis (p = .0012). Median survival time for dogs with lymph node metastasis was 551 days (110–2050) compared to 1722 days (10–1722) without metastasis (p = .0432). Local recurrence resulted in a significantly shorter median survival time of 551 days (80–2050) compared to 1722 days (10–1722) for dogs without local recurrence (p = .0038). Dogs with infiltrative tumors had a median DFI of 268 days (3–1722) and DFI for dogs without an infiltrative pattern had not reached median at 1864 days (10–1864) (p = .011).ConclusionLymph node metastasis decreased disease‐free interval and survival.Clinical significanceSubcutaneous mast cell tumors may be a more aggressive disease than previously reported.

Publisher

Wiley

Subject

General Veterinary

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3